HIV and Liver Disease 2023
September 7-9, 2023

Liver disease has emerged as a major cause of morbidity and mortality in individuals infected with HIV, including those infected with HBV and HCV. The HIV & Liver Disease 2023 conference is designed to address the increasingly prevalent clinical issues and challenges associated with HIV and liver disease. The conference brings together internationally renowned experts and clinicians from a variety of disciplines, including hepatology and infectious diseases, who will present and discuss the most current and clinically relevant information pertinent to improving patient outcomes.

This year the conference will be held live, in-person. It features General sessions, with presentations by faculty experts, Meet-the Professor lunch roundtable discussions, Oral presentations, and Poster presentations.

The conference will be held at Snake River Lodge, Teton Village, Wyoming.  read more »

SPONSORSHIPS

For sponsorship and table-top exhibit opportunities, please contact Amber Lovett at amber.lovett@uc.edu.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees' professional development.

Funding for this conference was made possible [in part] by the National Institutes of Health under Award Number R13AI071925 from the National Institute of Allery and Infectious Diseases (NIAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Funding was also made possible [in part] by the National Cancer Institute (NCI).

Supported by educational grants and sponsorships from:

Abbott Laboratories, Gilead, Theratechnologies, ViiV, and Vir Biotechnology, Inc.